- Home
- DNTH vs BRSP Comparison
DNTH vs BRSP Comparison
Compare DNTH & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- BRSP
- Stock Information
- Founded
- DNTH 2015
- BRSP 2017
- Country
- DNTH United States
- BRSP United States
- Employees
- DNTH N/A
- BRSP N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- DNTH Health Care
- BRSP Real Estate
- Exchange
- DNTH Nasdaq
- BRSP Nasdaq
- Market Cap
- DNTH 780.2M
- BRSP 665.4M
- IPO Year
- DNTH N/A
- BRSP 2018
- Fundamental
- Price
- DNTH $26.50
- BRSP $5.95
- Analyst Decision
- DNTH Strong Buy
- BRSP Buy
- Analyst Count
- DNTH 8
- BRSP 4
- Target Price
- DNTH $54.00
- BRSP $6.38
- AVG Volume (30 Days)
- DNTH 374.5K
- BRSP 618.5K
- Earning Date
- DNTH 11-06-2025
- BRSP 10-28-2025
- Dividend Yield
- DNTH N/A
- BRSP 10.77%
- EPS Growth
- DNTH N/A
- BRSP N/A
- EPS
- DNTH N/A
- BRSP N/A
- Revenue
- DNTH $4,854,000.00
- BRSP $335,107,000.00
- Revenue This Year
- DNTH N/A
- BRSP N/A
- Revenue Next Year
- DNTH N/A
- BRSP $6.22
- P/E Ratio
- DNTH N/A
- BRSP N/A
- Revenue Growth
- DNTH 17.87
- BRSP N/A
- 52 Week Low
- DNTH $13.37
- BRSP $4.16
- 52 Week High
- DNTH $32.27
- BRSP $6.45
- Technical
- Relative Strength Index (RSI)
- DNTH 70.68
- BRSP 70.29
- Support Level
- DNTH $22.81
- BRSP $5.69
- Resistance Level
- DNTH $24.81
- BRSP $5.82
- Average True Range (ATR)
- DNTH 1.57
- BRSP 0.11
- MACD
- DNTH 0.22
- BRSP 0.01
- Stochastic Oscillator
- DNTH 91.57
- BRSP 90.27
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.